| cancer vaccines nanoparticles | In many cases, the vaccine is not successfully designed because the candidate failed to elicit an appropriate immune response. Therefore, it is desirable to combine an immunomodulatory or adjuvant with an improved delivery vehicle to improve the quality of vaccine production. Creative Biolabs has experts in developing vaccine delivery vehicles, including nanoparticles, liposomes, micelles and immunostimulating complexes (ISCOM). Our vaccine delivery optimization strategy can provide you with the best advice and accelerate your vaccine development program. |